Spots Global Cancer Trial Database for sirolimus
Every month we try and update this database with for sirolimus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants | NCT01488253 | Acute Leukemia ... Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Sirolimus Tacrolimus | 20 Years - 60 Years | The Korean Society of Blood and Marrow Transplantation | |
| Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | NCT01537107 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu... | vismodegib sirolimus positron emissi... computed tomogr... pharmacological... laboratory biom... fludeoxyglucose... | 18 Years - | Mayo Clinic | |
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | NCT03217669 | Advanced Solid ... Non-small Cell ... | Epacadostat sirolimus | 18 Years - | University of Kansas Medical Center | |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | NCT04177004 | Allogeneic Hema... Hematopoietic a... | Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus | 12 Years - | City of Hope Medical Center | |
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome | NCT04893486 | BCCs in Gorlin ... | PTX-022 Vehicle compara... | 18 Years - | Palvella Therapeutics, Inc. | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | NCT00043979 | Sarcoma | F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo... | 5 Years - 35 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA) | NCT05549167 | Juvenile Nasoph... | Sirolimus | 7 Years - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | NCT02042326 | Arteriovenous M... | Sirolimus | 2 Years - | Centre Hospitalier Universitaire, Amiens | |
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | NCT02528877 | Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo... | Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus | NCT06236022 | Dilated Cardiom... Kaposi's Sarcom... | Sirolimus | 18 Years - 70 Years | Tongji Hospital | |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | NCT00923845 | Renal Cell Carc... Graft-Versus-Ho... Engraftment Syn... | Pentostatin Sirolimus Cyclophosphamid... Allogeneic Hema... Th2 rapa cells Donor Lymphocyt... Induction Thera... GVHD prophylaxi... Donor Hematopoi... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. | NCT04775173 | Kaposiform Hema... | Sirolimus | 1 Day - 14 Years | West China Hospital | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | NCT03225417 | Hematopoietic S... Multiple Myelom... | Ixazomib Tacrolimus Sirolimus Any prophylaxis... | 18 Years - | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | |
| Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma | NCT00450320 | Sarcoma | sirolimus | 18 Years - | AIDS Malignancy Consortium | |
| Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma | NCT01684449 | Advanced Soft T... | Gemcitabine + R... | 18 Years - 70 Years | Grupo Espanol de Investigacion en Sarcomas | |
| Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT01220297 | Hematologic Dis... Acute-graft-ver... Leukemia Non-Hodgkin Lym... Hodgkin Lymphom... | Sirolimus Mycophenolate m... Carmustine Etoposide Cyclophosphamid... FTBI | 2 Years - 60 Years | Stanford University | |
| Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH) | NCT04406870 | Hemangioendothe... | Sirolimus Oral ... propranolol | 1 Month - 36 Months | Shanghai Children's Medical Center | |
| Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | NCT00350181 | Leukemia Lymphoma, Non-H... Hematologic Dis... Acute GVHD | Sirolimus MMF BCNU VP-16 CY FTBI BU | 2 Years - 60 Years | Stanford University | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer | NCT02753309 | Bladder Cancer | Sirolimus | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT02565901 | Castration-Resi... Metastatic Pros... Stage IV Prosta... Metastatic Mali... | Carboplatin Docetaxel Laboratory Biom... Sirolimus | 18 Years - | University of Washington | |
| Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | NCT01303965 | Multiple Myelom... | Sirolimus Tacrolimus Lenalidomide | 18 Years - | Indiana University | |
| Weekly Sirolimus Therapy | NCT04861064 | Venous Malforma... Lymphatic Malfo... | Sirolimus | 2 Years - | Medical University of South Carolina | |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT02565901 | Castration-Resi... Metastatic Pros... Stage IV Prosta... Metastatic Mali... | Carboplatin Docetaxel Laboratory Biom... Sirolimus | 18 Years - | University of Washington | |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | NCT03970096 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col... | 1 Year - 60 Years | Fred Hutchinson Cancer Center | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus | NCT06236022 | Dilated Cardiom... Kaposi's Sarcom... | Sirolimus | 18 Years - 70 Years | Tongji Hospital | |
| Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations | NCT06080165 | PTEN Gene Mutat... PTEN Hamartoma ... PTEN Hamartoma ... | Sirolimus Placebo | 5 Years - 45 Years | Stanford University | |
| Sirolimus and Familial Adenomatous Polyposis (FAP) | NCT03095703 | Adenomatous Pol... | Sirolimus | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | NCT00133367 | Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... Myelogenous Leu... Lymphoblastic L... | Tacrolimus Sirolimus G-CSF Antithymocyte g... Thymoglobulin Fludarabine Melphalan | 18 Years - 65 Years | Massachusetts General Hospital | |
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases | NCT04083183 | Non-Malignant N... | Astatine At 211... Fludarabine Cyclophosphamid... Lapine T-Lympho... Total-Body Irra... Hematopoietic C... Mycophenolate M... Sirolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 49 Years | Fred Hutchinson Cancer Center | |
| Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens | NCT01428973 | Graft-Versus-Ho... Hematological M... | Mycophenolate m... Sirolimus | 16 Years - 75 Years | University of Liege | |
| Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00634244 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... | alvocidib mitoxantrone hy... carboplatin cytarabine sirolimus etoposide topotecan hydro... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Sirolimus for Retinal Astrocytic Hamartoma | NCT04707209 | Retinal Astrocy... | Sirolimus | 15 Years - 16 Years | The Hospital for Sick Children | |
| Topical Rapamycin to Erase Angiofibromas in TSC | NCT01526356 | Angiofibromas Tuberous Sclero... | Placebo Rapamycin Rapamycin | - | The University of Texas Health Science Center, Houston | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes | NCT00971789 | Cowden's Diseas... Hamartoma Syndr... | fludeoxyglucose... sirolimus Clinical Videog... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | NCT00406393 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... | Tacrolimus Methotrexate Sirolimus | 2 Years - 60 Years | Medical College of Wisconsin | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | NCT01379209 | Graft Versus Ho... | RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus | 18 Years - | Regimmune Corporation | |
| Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer | NCT04348292 | Lung Non-Small ... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Durvalumab Sirolimus | 18 Years - | Emory University | |
| Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH) | NCT04406870 | Hemangioendothe... | Sirolimus Oral ... propranolol | 1 Month - 36 Months | Shanghai Children's Medical Center | |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | NCT01534143 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | pharmacological... tacrolimus sirolimus anti-thymocyte ... fludarabine pho... busulfan bortezomib allogeneic hema... laboratory biom... | 18 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer | NCT00922129 | Prostate Cancer | Sirolimus (Rapa... Cyclosporin (Ne... | 18 Years - 50 Years | St. Joseph's Healthcare Hamilton | |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | NCT03433183 | Malignant Perip... Neurofibromatos... | Selumetinib Sirolimus | 12 Years - | Sarcoma Alliance for Research through Collaboration | |
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | NCT01625351 | Ewing Sarcoma Gastrointestina... Germ Cell Tumor Hepatic Tumor Lymphoma Wilms Tumor Rhabdoid Tumor Clear Cell Carc... Renal Cell Carc... Melanoma Neuroblastoma Rhabdomyosarcom... Non-rhabdomyosa... | alemtuzumab fludarabine sirolimus Busulfan melphalan stem cells CliniMACS | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | NCT00490789 | Tuberous Sclero... Lymphangioleiom... | sirolimus | 18 Years - 65 Years | Cardiff University | |
| Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | NCT00890500 | Hematologic Mal... Allogeneic Stem... | Fludarabine Melphalan Antithymocyte G... Sirolimus Tacrolimus | 18 Years - 65 Years | Fate Therapeutics | |
| Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma | NCT00355862 | Hepatocellular ... | CNI, MMF, Stero... Sirolimus | 18 Years - | University of Regensburg | |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | NCT00092222 | Lymphoprolifera... HHV-8 Malignancy HIV | Etoposide Interferon-alph... Rituximab Zidovudine Liposomal Doxor... Bortezomib Valganciclovir Doxorubicin Vincristine Cyclophosphamid... Filgrastim (G-C... Prednisone Sirolimus Observation Onl... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA) | NCT05549167 | Juvenile Nasoph... | Sirolimus | 7 Years - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors | NCT04469530 | Solid Tumor | Sirolimus Cyclophosphamid... Etoposide Celecoxib | 1 Year - 30 Years | Emory University | |
| A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors | NCT02110069 | Kaposiform Hema... Kasabach-Merrit... Tufted Angioma | Vincristine Sirolimus | - 31 Years | Boston Children's Hospital | |
| Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | NCT00780104 | Myeloid Leukemi... AML Leukemia CML | Rapamycin, Mito... Rapamycin + MEC | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | NCT06287944 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an... | 18 Years - | City of Hope Medical Center | |
| Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA) | NCT05549167 | Juvenile Nasoph... | Sirolimus | 7 Years - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH) | NCT04406870 | Hemangioendothe... | Sirolimus Oral ... propranolol | 1 Month - 36 Months | Shanghai Children's Medical Center | |
| A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis | NCT01265030 | Desmoid Tumor | Sirolimus | - 29 Years | MaineHealth | |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | NCT01231412 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Lymphoc... Diffuse Large B... Hematopoietic a... Indolent Non-Ho... Mantle Cell Lym... Myelodysplastic... Myeloproliferat... Prolymphocytic ... Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Chro... Refractory Hodg... Small Lymphocyt... T-Cell Chronic ... Waldenstrom Mac... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer | NCT04348292 | Lung Non-Small ... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Durvalumab Sirolimus | 18 Years - | Emory University | |
| Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | NCT00353301 | Renal Cell Carc... | Erlotinib hydro... Sirolimus | 18 Years - | University of Colorado, Denver | |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | NCT06239480 | Microcystic Lym... | QTORIN 3.9% Rap... Placebo | 6 Years - | Palvella Therapeutics, Inc. | |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03531281 | Hematopoietic a... Hematopoietic C... | Allogeneic Hema... Cyclophosphamid... Etoposide Goat Milk Laboratory Biom... Palifermin Sirolimus Tacrolimus Total-Body Irra... | 12 Years - 60 Years | City of Hope Medical Center | |
| Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | NCT03047980 | Sturge-Weber Sy... | Sirolimus | 3 Years - 31 Years | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
